CAR T cells in multiple myeloma: lessons learned
Nature Reviews Clinical Oncology, Published online: 07 May 2024; doi:10.1038/s41571-024-00898-8The question of whether chimeric antigen receptor (CAR) T cell therapies should be used in earlier lines (after 1–2 prior lines of therapy) in patients with relapsed and/or refractory multiple myeloma remains unanswered. Herein, I argue that the use of surrogate end points that lack a robust correlation with overall survival, as well as suboptimal control arms and use of post-progression therapies, limit the ability to make definitive conclusions on the basis of the available data. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - May 7, 2024 Category: Cancer & Oncology Authors: Vinay Prasad Source Type: research
NIR-II light in clinical oncology: opportunities and challenges
Nature Reviews Clinical Oncology, Published online: 01 May 2024; doi:10.1038/s41571-024-00892-0Expansion of the utilizable spectrum of light from the visible region to the near-infrared (NIR) window has greatly facilitated the clinical application of optical technologies for cancer imaging and phototherapy. However, use of light in the first NIR region (NIR-I) has important limitations, some of which might be overcome with emerging technologies utilizing NIR-II light. In this Review, the authors describe the current clinical experience with NIR-II-based cancer imaging and phototherapy, and discuss emerging NIR-II-based app...
Source: Nature Reviews Clinical Oncology - May 1, 2024 Category: Cancer & Oncology Authors: Zeyu Zhang Yang Du Xiaojing Shi Kun Wang Qiaojun Qu Qian Liang Xiaopeng Ma Kunshan He Chongwei Chi Jianqiang Tang Bo Liu Jiafu Ji Jun Wang Jiahong Dong Zhenhua Hu Jie Tian Source Type: research
Adjuvant pembrolizumab improves overall survival in patients with RCC
Nature Reviews Clinical Oncology, Published online: 29 April 2024; doi:10.1038/s41571-024-00901-2Adjuvant pembrolizumab improves overall survival in patients with RCC (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - April 29, 2024 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research
Laparoscopic hemihepatectomy is safe and effective
Nature Reviews Clinical Oncology, Published online: 29 April 2024; doi:10.1038/s41571-024-00900-3Laparoscopic hemihepatectomy is safe and effective (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - April 29, 2024 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research
NALIRIFOX for metastatic pancreatic adenocarcinoma: hope or hype?
Nature Reviews Clinical Oncology, Published online: 25 April 2024; doi:10.1038/s41571-024-00896-wThe FDA has approved nanoliposomal irinotecan, 5-fluorouracil, leucovorin and oxaliplatin (NALIRIFOX) for patients with metastatic pancreatic adenocarcinoma on the basis of results from the NAPOLI 3 trial, in which this four-drug regimen improved overall survival relative to a doublet regimen. Here we discuss how, in the context of prior results from the PRODIGE 4 trial testing 5-fluorouracil, leucovorin, irinotecan and oxaliplatin (modified FOLFIRINOX), NALIRIFOX does not seem to raise the bar, but rather exposes patients and ...
Source: Nature Reviews Clinical Oncology - April 25, 2024 Category: Cancer & Oncology Authors: Christopher Nevala-Plagemann Ignacio Garrido-Laguna Source Type: research
Adjuvant alectinib improves outcomes in ALK-mutant NSCLC
Nature Reviews Clinical Oncology, Published online: 25 April 2024; doi:10.1038/s41571-024-00899-7Adjuvant alectinib improves outcomes in ALK-mutant NSCLC (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - April 25, 2024 Category: Cancer & Oncology Authors: Diana Romero Source Type: research
From AACR 2024
Nature Reviews Clinical Oncology, Published online: 25 April 2024; doi:10.1038/s41571-024-00897-9From AACR 2024 (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - April 25, 2024 Category: Cancer & Oncology Authors: Diana Romero Source Type: research
Overtreatment of multiple myeloma and its precursor states: de-escalation is an urgent need in clinical practice and trials
Nature Reviews Clinical Oncology, Published online: 22 April 2024; doi:10.1038/s41571-024-00895-xCertain subsets of patients with multiple myeloma or its precursor conditions are overtreated with current approaches to therapy. Herein, we highlight several key areas where we believe de-escalation of treatment is needed. Dedicated trials to assess these de-escalation approaches and urgent changes to current clinical practices are needed. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - April 22, 2024 Category: Cancer & Oncology Authors: Ghulam Rehman Mohyuddin Aaron M. Goodman Source Type: research
Multiparametric MRI for characterization of the tumour microenvironment
Nature Reviews Clinical Oncology, Published online: 19 April 2024; doi:10.1038/s41571-024-00891-1By combining multiple MRI sequences, each providing different but complementary information about the tumour microenvironment (TME), multiparametric MRI (mpMRI) enables non-invasive assessment of the heterogeneous features of the TME components. The authors of this Review describe the role of mpMRI in the non-invasive characterization of the TME, presenting examples of its utility in cancer detection, staging and assessment of response to therapy, and considering future applications for personalized integrated diagnostics. (Sou...
Source: Nature Reviews Clinical Oncology - April 19, 2024 Category: Cancer & Oncology Authors: Emily Hoffmann Max Masthoff Wolfgang G. Kunz Max Seidensticker Stefanie Bobe Mirjam Gerwing Wolfgang E. Berdel Christoph Schliemann Cornelius Faber Moritz Wildgruber Source Type: research
Afami-cel provides a novel treatment option for rare sarcoma subtypes
Nature Reviews Clinical Oncology, Published online: 18 April 2024; doi:10.1038/s41571-024-00894-yAfami-cel provides a novel treatment option for rare sarcoma subtypes (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - April 18, 2024 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research
ALND can be safely omitted for patients with sentinel-node macrometastases
Nature Reviews Clinical Oncology, Published online: 18 April 2024; doi:10.1038/s41571-024-00893-zALND can be safely omitted for patients with sentinel-node macrometastases (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - April 18, 2024 Category: Cancer & Oncology Authors: David Killock Source Type: research
Lighting the torch: intratumoural T cell-to-stroma enrichment score as a predictor of immunotherapy response in urothelial carcinoma
Nature Reviews Clinical Oncology, Published online: 15 April 2024; doi:10.1038/s41571-024-00890-2T cell infiltration in the tumour microenvironment (TME) is a prerequisite for sustained antitumour immune responses. However, identifying predictive biomarkers that quantify T cell infiltration and the presence of proinflammatory TMEs associated with immune-checkpoint inhibitor (ICI) response for clinical implementation has proved challenging. Here, we highlight a study that validates a T cell-to-stroma enrichment score generated from RNA sequencing data as a novel biomarker for ICI response in patients with urothelial carcino...
Source: Nature Reviews Clinical Oncology - April 15, 2024 Category: Cancer & Oncology Authors: David H. Aggen Jonathan E. Rosenberg Source Type: research
Antiangiogenic–immune-checkpoint inhibitor combinations: lessons from phase III clinical trials
Nature Reviews Clinical Oncology, Published online: 10 April 2024; doi:10.1038/s41571-024-00886-yThe benefit of combining antiangiogenic agents with immune-checkpoint inhibitors has been demonstrated in pivotal phase III trials across different cancer types, some with practice-changing results; however, other phase III trials have had negative results. The authors of this Perspective discuss the variable outcomes of these trials, considering factors that account for these differences and suggesting future initiatives for improving the outcomes in patients receiving these combinations. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - April 10, 2024 Category: Cancer & Oncology Authors: Hung-Yang Kuo Kabir A. Khan Robert S. Kerbel Source Type: research
Nucleic acid-based drugs for patients with solid tumours
Nature Reviews Clinical Oncology, Published online: 08 April 2024; doi:10.1038/s41571-024-00883-1Nucleic acid-based therapies offer an alternative to traditional cancer treatment modalities, with promising data beginning to emerge. In this Review, the authors describe the design and development of nucleic acid-based therapies administered virally and non-virally, including discussions of the advantages and disadvantage of each approach, as well as the role of patient-specific factors such as the tumour microenvironment, and consider the most promising future research directions. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - April 8, 2024 Category: Cancer & Oncology Authors: Sebastian G. Huayamares David Loughrey Hyejin Kim James E. Dahlman Eric J. Sorscher Source Type: research
Pembrolizumab plus chemoradiotherapy effective in locally advanced cervical cancer
Nature Reviews Clinical Oncology, Published online: 02 April 2024; doi:10.1038/s41571-024-00889-9Pembrolizumab plus chemoradiotherapy effective in locally advanced cervical cancer (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - April 2, 2024 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research
